HeraMEDASX:HMD -2.63% FCF Yield % is -8.53 as of Jun. 30, 2026. The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, HeraMED ranks worse than 71.78% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, HeraMED's Trailing 12-Month Free Cash Flow is A$-3.66 Mil, and Market Cap is A$42.87 Mil. Therefore, HeraMED's FCF Yield % for today is -8.53%.
The historical rank and industry rank for HeraMED's FCF Yield % or its related term are showing as below:
ASX:HMD'
s FCF Yield % Range Over the Past 10 Years
Min: -149.54 Med: -26.57 Max: -8.31
Current: -8.53
During the past 8 years, the highest FCF Yield % of HeraMED was -8.31%. The lowest was -149.54%. And the median was -26.57%.
ASX:HMD's FCF Yield % is ranked worse than 71.78% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: -0.385
vs ASX:HMD: -8.53
HeraMED's FCF Margin % for the quarter that ended in Dec. 2025 was -1,118.83%.
HeraMED FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
HeraMED FCF Yield % Related Terms
HeraMED FCF Yield % Historical Data
* Premium members only.
The historical data trend for HeraMED's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, HeraMED's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeraMED FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's FCF Yield % distribution charts can be found below:
* The bar in red indicates where HeraMED's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (ASX:HMD) has a FCF Yield % of -8.53 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on HeraMED and its competitors. According to the industry distribution chart, HeraMED ranks #613 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 71.8%.
Is HeraMED's FCF Yield % too high?
HeraMED's current FCF Yield % is -8.53. Based on the distribution chart, HeraMED ranks #613 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does HeraMED's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #613 out of 854 companies for FCF Yield %. This places HeraMED in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on HeraMED and its competitors. HeraMED's current FCF Yield % is -8.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 85% above its estimated fair value. The current FCF Yield % is -8.53. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current FCF Yield % is -8.53 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HMD has been successfully added to your 